Jiangsu Chengxin Pharmaceutical

Jiangsu Chengxin Pharmaceutical is a China-based pharmaceutical company that specializes in the research, development, and manufacturing of high-end Active Pharmaceutical Ingredients (APIs) and intermediates. The company is a leader in the production of nucleoside and nucleotide products, utilizing an advanced enzymatic synthesis platform to create high-purity compounds. Its core portfolio includes Citicoline Sodium, Glutathione, and Ademetionine, which are primarily used to treat neurological, hepatic, and psychiatric conditions. In 2020, the company was acquired by Nanjing King-Friend Biochemical Pharmaceutical, a move that integrated Chengxin's specialized manufacturing capabilities into a broader global pharmaceutical supply chain. Jiangsu Chengxin operates state-of-the-art GMP-compliant facilities in Yancheng and provides comprehensive CDMO services to global partners.